Supplemental Information: OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)

  1. Date of occurrence of the event: January 26, 2017
  2. Company name: OBI Pharma, Inc.
  3. Relationship to the Company (please enter ”head office” or ”affiliated company”): Head office
  4. Reciprocal shareholding ratios: N/A
  5. Name of mass media: N/A
  6. Content reported: N/A
  7. Cause of occurrence: China Food and Drug Administration (CFDA) authorized a multi-center Phase III clinical trial in Asia for the novel breast cancer drug Adagloxad Simolenin (OBI-822, also known as OPT-822). The planning of its indication, trial design, number of participants, and trial schedule will be based on comprehensive consideration of the OBI-822 global clinical trial development strategy.
  8. Countermeasures: Please refer to the information disclosed on for regarding financial affairs and R&D progress.
  9. Any other matters that need to be specified: New drug development is a long journey associated with high cost. It is not a guaranteed success, which may increase the risk of investment. Investors shall make prudent judgments and investments.